Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

Boehringer Ingelheim

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Study type: Observational

Funder types: Industry

Identifiers

NCT02191202

1100.1461

Details and patient eligibility

About

Observational study to evaluate therapeutic switch to a NNRTI-based regimen on quality of life of HIV-positive patients

Enrollment: 283 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• NNRTI-naive patients with positive HIV serology, treated with at least triple combination therapy, with a viral load < 500 copies/ml, in whom a new treatment comprising an NNRTI is initiated for a reason other than inefficacy of treatment will be included
• Patients must read and write French

Exclusion criteria

• Patients in whom a new treatment is initiated because of treatment failure
• new treatment does not comprise an NNRTI

Trial design

283 participants in 1 patient group

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Treatment:

Drug: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)